National Pension Service Buys New Position in DaVita Inc. $DVA

National Pension Service purchased a new position in shares of DaVita Inc. (NYSE:DVA) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 9,822 shares of the company’s stock, valued at approximately $1,305,000.

Several other hedge funds and other institutional investors have also made changes to their positions in DVA. NewEdge Advisors LLC grew its holdings in shares of DaVita by 20.8% in the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after purchasing an additional 88 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in DaVita by 19.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock valued at $27,403,000 after buying an additional 28,739 shares during the period. Truist Financial Corp grew its stake in shares of DaVita by 1.9% in the second quarter. Truist Financial Corp now owns 8,646 shares of the company’s stock worth $1,232,000 after acquiring an additional 163 shares in the last quarter. Ameritas Advisory Services LLC purchased a new stake in shares of DaVita during the second quarter worth $47,000. Finally, KLP Kapitalforvaltning AS raised its stake in shares of DaVita by 1.1% in the second quarter. KLP Kapitalforvaltning AS now owns 28,614 shares of the company’s stock valued at $4,076,000 after acquiring an additional 300 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on DVA shares. Truist Financial lowered their target price on DaVita from $140.00 to $128.00 and set a “hold” rating for the company in a research note on Monday, January 5th. Zacks Research raised DaVita from a “strong sell” rating to a “hold” rating in a research report on Friday, November 28th. TD Cowen reaffirmed a “hold” rating on shares of DaVita in a report on Tuesday. UBS Group reiterated a “buy” rating on shares of DaVita in a research note on Monday, December 15th. Finally, Barclays increased their price objective on shares of DaVita from $143.00 to $158.00 and gave the company an “equal weight” rating in a research report on Tuesday. One analyst has rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $148.60.

Key Headlines Impacting DaVita

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: Q4 beat — DaVita reported Q4 revenue of ~$3.62B and EPS above estimates, with margins expanding and full‑year adjusted EPS guidance raised materially above consensus, supporting a more bullish near‑term outlook. DaVita Stock Up Following Q4 Earnings & Revenue Beat, Margins Expand
• Positive Sentiment: Raised guidance — Management set FY‑2026 EPS guidance of $13.60–$15.00, above the Street, citing steady dialysis demand; that forward guidance was a key catalyst for the stock’s rally. DaVita forecasts 2026 profit above estimates on steady dialysis service demand
• Positive Sentiment: After‑hours flow and market reaction — Major outlets reported strong after‑hours buying and a sizable volume spike as investors repositioned around the beats and higher guidance. Stocks making the biggest moves after hours: Palantir, NXP Semiconductors, DaVita and more
• Neutral Sentiment: Management commentary & call — The company’s press release and earnings call described execution vs targets and patient demand trends; read the transcript/press release for management’s assumptions driving the guidance. DaVita Inc. 4th Quarter 2025 Results
• Neutral Sentiment: Analyst context — Recent price targets cluster near the low‑to‑mid $100s–$140s range (median ~$140), so the new guidance will force analysts to re‑rate estimates and targets in coming days. DaVita Inc. Releases Q4 2025 Earnings
• Negative Sentiment: Volatility & risk factors — Market commentary warns that reimbursement, regulatory changes and execution risks could keep the stock volatile despite the beat; investors should expect swings. DaVita: Some Success Is Possible, But Volatility Is Still Heavy
• Negative Sentiment: Some financials to watch — While EPS and revenue improved, third‑party summaries show cash & cash equivalents declined and liabilities rose year‑over‑year; monitor margin sustainability and cash/leveraging metrics. DaVita Inc. Releases Q4 2025 Earnings (financial highlights)

DaVita Trading Up 21.0%

Shares of NYSE:DVA opened at $134.55 on Wednesday. The firm has a 50 day simple moving average of $113.69 and a 200-day simple moving average of $124.82. DaVita Inc. has a twelve month low of $101.00 and a twelve month high of $178.47. The company has a market capitalization of $9.50 billion, a PE ratio of 13.58, a P/E/G ratio of 0.68 and a beta of 0.99.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Monday, February 2nd. The company reported $3.40 EPS for the quarter, topping the consensus estimate of $3.24 by $0.16. DaVita had a net margin of 5.47% and a negative return on equity of 586.45%. The firm had revenue of $3.62 billion for the quarter, compared to analyst estimates of $3.51 billion. During the same period last year, the business earned $2.24 EPS. DaVita’s revenue for the quarter was up 9.9% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. As a group, equities research analysts predict that DaVita Inc. will post 10.76 EPS for the current fiscal year.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.